{
  "nctrialId": "HC-1611",
  "title": "A  Double-Blind, Active-Controlled  Study of BRE-701 (selective estrogen receptor modulator) in Patients With Hypertension",
  "officialTitle": "A  Double-Blind, Active-Controlled  Study of BRE-701 (selective estrogen receptor modulator) in Patients With Hypertension",
  "sponsor": "University of Alberta",
  "indication": "Hypertension",
  "phase": "Phase 2/Phase 3",
  "fileName": "HC-1611.json",
  "fileSize": 462751,
  "date": "2024-02-02",
  "completionDate": "2026-02-23",
  "drugName": "BRE-701 (selective estrogen receptor modulator)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a  double-blind, active-controlled  study designed to evaluate the efficacy and safety of BRE-701 (selective estrogen receptor modulator) in patients with Hypertension. The study will enroll approximately 242 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 21-63 years\n- Confirmed diagnosis of Hypertension\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}